"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
Descriptor ID |
D065427
|
MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 2 | 2 |
2004 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 2 | 1 | 3 |
2012 | 1 | 1 | 2 |
2014 | 1 | 1 | 2 |
2015 | 3 | 3 | 6 |
2016 | 5 | 2 | 7 |
2017 | 1 | 2 | 3 |
2018 | 2 | 2 | 4 |
2019 | 6 | 0 | 6 |
2020 | 3 | 2 | 5 |
2021 | 1 | 0 | 1 |
2022 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost. 2023 06; 21(6):1601-1609.
-
Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. Pharmacotherapy. 2022 10; 42(10):768-779.
-
Managing bleeding risk after cold snare polypectomy in patients receiving direct-acting oral anticoagulants. Gastrointest Endosc. 2022 05; 95(5):969-974.
-
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach. J Clin Pharmacol. 2022 06; 62(6):733-746.
-
Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors? Am J Emerg Med. 2022 01; 51:426.e5-426.e7.
-
Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State. Ann Neurol. 2021 03; 89(3):444-458.
-
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
-
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020 08; 51(8):2386-2394.
-
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. Stroke. 2020 07; 51(7):2139-2147.
-
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices. Gen Thorac Cardiovasc Surg. 2020 Nov; 68(11):1278-1284.